China's NMPA approves batoclimab injection for myasthenia gravis
HBM Holdings Ltd said China's NMPA has approved its batoclimab injection for generalized myasthenia gravis, according to Reuters.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
HBM Holdings Ltd said China's NMPA has approved its batoclimab injection for treating generalized myasthenia gravis. Reuters reported the news based on the company's statement.
The story concerns a single drug and a single company, so it is unlikely to have a broad effect on markets.
why it matters
For HBM Holdings shareholders, approval in China could be an important step for the drug's commercial prospects, but for the wider market the event remains local.
tags
instruments
sources
- HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis — Reuters, 23 October 2026 at 01:35 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗